Catch up with our insights on the big issues in pharma.
Our thought leadership library brings you our latest data-driven reports, infographics and articles that tackle the big issues, interesting niches and everything in between.
Biopharma deal-making rebounded strongly in 2025, with rising confidence, larger transactions, and record alliance values shaping the year. Our latest Deal-making Roundup brings together the key numbers,...
Biopharma capital returned in 2025. But not for everyone.
After a significant dry spell, capital began to flow back into biopharma in 2025. Though not everyone benefited.
Deals were fewer but larger. Venture...
Orphan drug developers are navigating a more complex landscape.
FDA decision making has proved unpredictable, and rare disease programs must compete for attention as investment flows toward obesity and...
Orphan drugs are still growing. But the environment they operate in is changing fast.
Rare disease therapies are forecast to generate over $400bn in global sales and represent more than 21% of prescription...
A top 20 pharmaceutical company was overwhelmed by the daily volume of competitive activity and needed a way to focus on the updates that truly mattered.
See how Evaluate delivered a customized CI program...
#JPM2026 Post-Event Report
Your definitive guide to the biggest announcements and takeaways from this year’s most influential healthcare summit. See our roundup of mega cap, large cap, mid cap, small cap,...
